StockData
Mustang Bio, Inc. logo

Mustang Bio, Inc. (MBIO) shareholders

MBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.38−0.01 (-2.56%)

Close on Nov 18, 2026Market cap $2.88MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
7.1%
1M of 8M shares
Institutional holders
23
5 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
1 buys · 2 sales
Net sold $4

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Fortress Biotech, Inc.537,2438.00%13D (active) amendmentJan 2, 2026
Daniel B. Asher
Joint filing with Mitchell P. Kopin (8.80%), Intracoastal Capital LLC (8.80%)
236,4528.80%13G (passive) amendmentMar 31, 2025
Mitchell P. Kopin
Joint filing with Daniel B. Asher (9.99%), Intracoastal Capital LLC (9.99%)
186,5529.99%13G (passive)Feb 5, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MBIOValueChange% of portfolio
Kestra Advisory Services, LLC196,9912.60%$138.29K+20,9490.00%
BlackRock, Inc.84,7451.12%$59.49K–0.00%
Citadel Advisors LLC59,4590.78%$41.74K+6,2590.00%
Geode Capital Management, LLC42,2400.56%$29.65K−50,5500.00%
CFO4Life Group, LLC33,5100.44%$23.52K+13,0490.00%
Vanguard Fiduciary Trust Co32,1200.42%$22.55K–0.00%
Vanguard Capital Management LLC25,7040.34%$18.04K–0.00%
XTX Topco Ltd14,6480.19%$10.28KNew0.00%
Virtu Financial LLC14,3560.19%$10.00KNew0.00%
Two Sigma Securities, LLC13,7420.18%$9.65KNew0.00%
Susquehanna International Group, Llp13,6640.18%$9.59KNew0.00%
UBS Group AG4,1550.05%$2.92K+4960.00%
Tower Research Capital LLC (TRC)1,8950.03%$1.33K–0.00%
Barclays PLC1,1210.01%$787New0.00%
SBI Securities Co., Ltd.5090.01%$357–0.00%
Morgan Stanley1180.00%$83–0.00%
Cullen/Frost Bankers, Inc.130.00%$9–0.00%
Bnp Paribas Arbitrage, Snc60.00%$4–0.00%
Nbc Securities, Inc.30.00%$2–0.00%
JPMorgan Chase & Co20.00%$1–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026231M7.1%5 / 41 / 30M0M
Q1 2026221M6.7%4 / 54 / 60M0M
Q4 2025251M7.3%7 / 64 / 20M0M
Q3 2025200M3.7%6 / 63 / 30M0M
Q2 2025170M1.0%3 / 43 / 20M0M
Q1 2025160M1.5%2 / 75 / 160M0M
Q4 2024300M1.2%11 / 64 / 60M0M
Q3 2024250M0.2%5 / 54 / 70M0M
Q2 2024290M0.2%9 / 65 / 100M0M
Q1 2024300M0.2%6 / 67 / 40M0M
Q4 2023280M0.3%4 / 64 / 30M0M
Q3 2023270M0.2%4 / 36 / 40M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

5 funds held MBIO in Q2 2026, 22% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of MBIOValue% of fundAs of
Fidelity Extended Market Index Fund84,1441.11%$56.38K0.00%May 31, 2026
Vanguard Extended Market Index Fund25,7040.34%$18.04K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund4,1840.06%$2.80K0.00%May 31, 2026
Fidelity Total Market Index Fund1,0770.01%$7220.00%May 31, 2026
Nomura Healthcare Fund1600.00%$1120.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Manuel Litchman MDPresident, CEO and Interim CFO, Director1,6150.02%Apr 27, 2026
Neil HerskowitzDirector1450.00%Dec 30, 2025
Adam J. ChillDirector3750.00%Dec 30, 2025
David JinDirector2860.00%Dec 30, 2025
Fortress Biotech, Inc.10% owner536,5777.08%Jan 5, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Manuel Litchman MD
President, CEO and Interim CFO, Director
Apr 24, 2026Tax withholding−19$0.75$141,615
Fortress Biotech, Inc.
10% owner
Jan 2, 2026Award+278,385––536,577
David Jin
Director
Dec 30, 2025Buy+247$0.96$237286
Neil Herskowitz
Director
Dec 30, 2025Sale−247$0.96$237145
Adam J. Chill
Director
Dec 30, 2025Sale−4$0.95$4375
Fortress Biotech, Inc.
10% owner
Sep 29, 2025Award+59,334––258,192
Manuel Litchman MD
President, CEO and Interim CFO, Director
Apr 24, 2025Tax withholding−27$1.24$331,634
Fortress Biotech, Inc.
10% owner
Mar 31, 2025Award+67,806––198,858
Fortress Biotech, Inc.
10% owner
Jun 27, 2024Award+575,191––2,502,991
Manuel Litchman MD
President and CEO, Director
May 31, 2024Tax withholding−1,396$0.35$48983,024
Fortress Biotech, Inc.
10% owner
Jan 2, 2024Award+419,092––1,927,800
Adam J. Chill
Director
Jul 5, 2023Award+7,246––19,170
Neil Herskowitz
Director
Jul 5, 2023Award+7,246––19,703
Lindsay A. Rosenwald Md
Director
Jul 5, 2023Award+7,246––60,525
Michael S. Weiss
Director
Jul 5, 2023Award+7,246––49,637
Michael J. Zelefsky
Director
Jul 5, 2023Award+7,246––18,970
Manuel Litchman MD
President and CEO, Director
Apr 24, 2023Tax withholding−1,572$4.21$6.62K79,420
Manuel Litchman MD
President and CEO, Director
Apr 24, 2023Award+5,000––111,079
Fortress Biotech, Inc.
10% owner
Jan 6, 2023Award+2,807,008––22,630,620
Manuel Litchman MD
Director
Sep 13, 2022Buy+5,000$0.52$2.60K1,098,987
Lindsay A. Rosenwald Md
Director
Sep 13, 2022Buy+5,000$0.52$2.60K299,181
Michael J. Zelefsky
Director
Jul 29, 2022Award+71,664––175,861
Adam J. Chill
Director
Jul 29, 2022Award+71,664––178,861
Neil Herskowitz
Director
Jul 29, 2022Award+71,664––186,861
Michael S. Weiss
Director
Jul 29, 2022Award+71,664––135,861
Lindsay A. Rosenwald Md
Director
Jul 29, 2022Award+71,664––294,181
Manuel Litchman MD
Director
Jun 21, 2022Award+61,000––1,093,987
Manuel Litchman MD
President and CEO, Director
Apr 24, 2022Tax withholding−1,248$12.15$15.16K80,992
Manuel Litchman MD
Director
Mar 18, 2022Buy+5,000$0.74$3.70K1,032,987
Lindsay A. Rosenwald Md
Director
Mar 18, 2022Buy+4,094$0.74$3.03K222,517
Brian Achenbach
SVP, Fin. & Corp. Controller
Dec 14, 2021Sale−4,374$1.83$8.00K144,729
Brian Achenbach
SVP, Fin. & Corp. Controller
Dec 8, 2021Award+22,500––149,103
Manuel Litchman MD
President and CEO, Director
Oct 27, 2021Buy+65,000$2.24$145.60K1,027,987
Brian Achenbach
SVP, Fin. & Corp. Controller
Oct 12, 2021Sale−4,450$2.28$10.15K126,603
Lindsay A. Rosenwald Md
Director
Aug 31, 2021Award+1,170$2.58$3.02K218,423
Manuel Litchman MD
President and CEO, Director
Aug 31, 2021Award+2,746$2.58$7.08K962,987
Manuel Litchman MD
President and CEO, Director
Jul 30, 2021Buy+86,206$2.91$250.86K960,241
Michael S. Weiss
Director
Jun 28, 2021Award+13,774––64,197
Lindsay A. Rosenwald Md
Director
Jun 28, 2021Award+13,774––217,253
Neil Herskowitz
Director
Jun 28, 2021Award+13,774––115,197
Adam J. Chill
Director
Jun 28, 2021Award+13,774––107,197
Michael J. Zelefsky
Director
Jun 28, 2021Award+13,774––104,197
Manuel Litchman MD
President and CEO, Director
Jun 17, 2021Award+61,000––874,035
Brian Achenbach
SVP, Fin. & Corp. Controller
Apr 9, 2021Sale−2,423$3.36$8.14K131,053
Manuel Litchman MD
President and CEO, Director
Mar 5, 2021Buy+165,562$3.12$516.55K825,408
Manuel Litchman MD
President and CEO, Director
Feb 26, 2021Award+5,000$2.83$14.15K659,846
Lindsay A. Rosenwald Md
Director
Feb 26, 2021Award+1,043$2.83$2.95K203,479
Brian Achenbach
SVP, Fin. & Corp. Controller
Dec 15, 2020Award+22,500––151,774
Manuel Litchman MD
President and CEO, Director
Dec 15, 2020Buy+100,000$2.91$291.00K654,846
Lindsay A. Rosenwald Md
Director
Dec 14, 2020Buy+100,000$2.66$266.00K202,436
Lindsay A. Rosenwald Md
Director
Dec 14, 2020Buy+100,000$2.66$266.00K200,423
Brian Achenbach
SVP, Fin. & Corp. Controller
Dec 8, 2020Sale−5,185$3.03$15.71K133,476
Brian Achenbach
SVP, Fin. & Corp. Controller
Oct 21, 2020Sale−3,056$2.97$9.08K138,661
Manuel Litchman MD
President and CEO, Director
Sep 15, 2020Award+61,000––554,846
Lindsay A. Rosenwald Md
Director
Aug 31, 2020Award+1,182$2.48$2.93K102,436
Manuel Litchman MD
President and CEO, Director
Aug 31, 2020Award+5,000$2.48$12.40K493,846
Lindsay A. Rosenwald Md
Director
Jul 14, 2020Award+16,611$2.48$41.20K101,254
Neil Herskowitz
Director
Jul 14, 2020Award+16,611––101,423
Lindsay A. Rosenwald Md
Director
Jul 14, 2020Award+16,611––100,423
Adam J. Chill
Director
Jul 14, 2020Award+16,611––93,423

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
1.00%
0M shares short
Days to cover
2.8
At 0M shares a day
Change since last report
+19.3%
From 0M shares
Short volume, 20 days
31.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Mustang Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,206 shares on Sep 8, 2026 over the last 90 days.

See a number that looks wrong?